3 in E. Coli BL21 (DE3, Novagen) (Moggs et al, 2000) , purified on glutathione beads (17-0756-01, GE Healthcare) and eluted with 10mM glutathione according to the manufacturer's instructions. We verified the specificity of both Asf1a and Asf1b antibodies as described in Supplementary Figure S1 . Supplementary Table SI lists all primary antibodies used in this study with their source, reference, and dilutions for western blotting or immunofluorescence.
Immunofluorescence microscopy
Cells grown on coverslips, fixed in 2% paraformaldehyde, and permeabilized in PBS containing 0,2% Triton X-100, were processed as in (Martini et al, 1998) . For lamin A staining, a pre-extraction step was performed to remove soluble proteins. Briefly, cells were washed with CSK, extracted with CSK 0.5% Triton X-100 and rinsed with CSK and PBS before fixation as described above. We used cross-absorbed Alexa-488 or Alexa-594 conjugated secondary antibodies (Molecular probes-Invitrogen) to detect primary antibodies (Supplementary Table SI) . We acquired images with a DM600 (Leica) upright widefield epifluorescence microscope (63X objective/NA 1.32 or 40X objective/NA 1.0) piloted with Metamorph software and equipped with a chilled CCD camera (CoolSnap Hq2, Photometrics). We applied identical settings and the same contrast adjustment for all images to allow accurate data comparison, except for LaminA staining on Figure 4C which was specifically enhanced in Asf1b depleted cells in order to visualize the DNA bridges. For brightness and contrast adjustment, we used Adobe Photoshop CS3 (Adobe). For quantitative analysis, a minimum number of n=100 nuclei were counted per experiment.
RNA extraction and Quantitative RT-PCR
We performed all reverse transcription using Superscript II reverse transcriptase (Invitrogen) with 500ng-1µg of RNA and 300ng-3µg of random primers (Invitrogen) per reaction respectively. For quantitative PCR analysis, we used the 96-well plate Step One Plus system (Applied Biosystems) and the SYBR Green PCR Master mix (Applied Biosystems) or the KAPA SYBR® FAST ABI Prism® 2X qPCR Master Mix (KAPA Biosystems) and filled plates using an EpMotion 5070 Robot (Eppendorf). We measured duplicates in all experiments and checked the efficiency of each primer pair (sequences below) with three subsequent cDNA dilutions for each of the breast tumor samples. For each gene, we normalized the quantity of mRNA to the quantity of mRNA corresponding to the human acidic ribosomal phosphoprotein PO (RPLPO) (de Cremoux et al, 2004) or to the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) . To compare with our transcriptome 4 analysis, we plotted mRNA levels relative to control siRNA levels and took logarithmic 2 values. This is referred to as the log2(fold change).
Primers
For analysis of the 86 and 71 breast tumor samples from 1995 and 1996 respectively, we used the following primers: Asf1a Forward: CAGATGCAGATGCAGTAGGC; Asf1a Reverse: CCTGGGATTAGATGCCAAAA; Asf1b Forward: GGTTCGAGATCAGCTTCGAG; Asf1b
Reverse:
CATGGTAGGTGCAGGTGATG; CAF-1 p60 Forward:
CGGACACTCCACCAAGTTCT; CAF-1 p60 Reverse: CCAGGCGTCTCTGACTGAAT;
CAF-1 p150 Forward: CAGCAGTACCAGTCCCTTCC; CAF-1 p150 Reverse:
TCTTTGCAGTCTGAGCTTGTTC; RPLPO Forward: GGCGACCTGGAAGTCCAACT; RPLPO Reverse: CCATCAGCACCACAGCCTTC; GAPDH Forward:
GAGTCAACGGATTTGGTCGT; GAPDH Reverse: TTGATTTTGGAGGGATCTCG. All other primer sequences used are available upon request.
Western blot quantification by chemiluminescence
For quantification, we performed acquisition of the chemiluminescence signal on a ChemiDoc XRS (BioRad) geldoc, and quantification of the intensity of the bands with Quantity One 4.6.6 software. We checked that the signal response is in a linear range using dilution series. We normalized values obtained for Asf1a or Asf1b levels to the levels of α-tubulin, or to the Memcode (Invitrogen) protein staining in the case of the mammary cell lines.
Transcriptome analysis
We used the package arrayQualityMetrics (Kauffmann et al, 2009 ) of the Bioconductor Project (Gentleman et al, 2004) for quality assessment to check for artifacts and quality issues with the eight arrays. (Birney et al, 2004) , and disregards probes that show potential cross-hybridization to transcripts of other genes. These alternate chip description files have been shown to outperform the standard chip description files supplied by the array manufacturer (Dai et al, 2005) . We normalized and log-transformed the probe intensities using the Bioconductor package vsn (Huber et al, 2002) ; we summarized the transformed probe intensities into gene (probe set) expression values using Tukey's median-polish procedure.
We determined differentially expressed genes using the Bioconductor package limma (Smyth, 2004) . For each gene, we constructed a linear model that relates the expression value of the gene in the eight samples to a common intercept, an effect for the presence of the siRNA against Asf1a (siAsf1a) and an effect for the presence of the siRNA against Asf1b (siAsf1b).
For each gene, a one-sample t-test was used to determine if the effects of siAsf1a and/or siAsf1b were significantly different from zero. For each test the variance of the gene term was shrunk towards an overall variance using the Empirical Bayes procedure of the Bioconductor package limma. We corrected the significant p-values of the t-tests for multiple testing by controlling the False Discovery Rate (Benjamini et al, 2001 To investigate whether the resulting lists of differentially expressed genes had significant association with Gene Ontology terms (Ashburner et al, 2000) , we used the Bioconductor package topGO (Alexa et al, 2006) . We obtained the Gene Ontology (GO) annotation of genes on the microarray from the Ensembl database in March 2009. We disregarded the associations between genes and GO terms which were solely inferred from electronic annotation (GO evidence terms: IEA, NAS, ND). To mitigate the dependencies between the tests imposed by the structure of the GO, if a gene was counted for the annotation of a specific gene, it was not counted again for any ancestor terms of this term ("elim" method of the package topGO). For each term, we performed a Hypergeometric test to determine whether genes of that list showed a more frequent association with a certain term than would be expected by chance given the GO annotation of all genes represented on the microarray.
When the test resulted in a p-value inferior to 5.10 -4 , we considered these terms as significantly over-represented for the given list.
In addition, we investigated the expression of Asf1a and Asf1b in another expression microarray data set. We performed quality assessment and preprocessing of this data set as described above. We performed comparisons of the expression levels of Asf1a and Asf1b between sample groups by using two-sample Wilcoxon rank-sum tests. We corrected significant p-values (p ≤ 0.05) of these tests for multiple testing using the Bonferroni method.
Breast tumor samples and statistics
We used samples from patients of 1995 with breast tumor classified as non-palpable (T0) or small (T1-T2) selected at the Institut Curie Biological Resources Center and treated with primary conservative tumorectomy (median tumor size: 18mm, range: 6-50mm). 92 patients diagnosed in 1995 and found to be lymph node negative (N0) and metastasis free (M0) granted permission to use their sample and data for research purposes. The median follow-up of the patients was 146 months (range: 30-161 months). Recurrence-free and alive patients were censored to the date of their last known contact. At the date of the analysis, 11% of the patients were no longer alive, with cause of death being the initial breast cancer in 70% of these cases. 10% of patients developed loco-regional recurrence and 15% developed metastasis. In addition, to confirm results obtained on the first set of tumors from 1995, we included a second independent set of patient samples from 1996 similar on all points to the first set. Patients and tumor characteristics are shown in Table SII and Supplementary Figure   S8B .
We selected RNA extracted from 86 (set of 1995) or 71 (set of 1996) cryofrozen tissue of sufficient quality for analysis by RT-QPCR. For each gene, we expressed the quantity x of the gene mRNA relative to the quantity of RPLPO mRNA in a given sample by applying x=100*(E^(Cp RPLPO -Cp Gene)), where E is the mean efficiency of the primers. For statistical analysis, we retained data from 55 patients (1995) for Asf1a, 85 (1995 Asf1a, 85 ( ) or 69 patients (1996 for Asf1b, 75 (1995 Asf1b, 75 ( ) or 70 patients (1996 for CAF-1 p60 and 86 (1995) or 71 (1996) patients for CAF-1 p150 which fulfilled our amplification criteria (reproducible duplicates, consistent primer efficiency between samples). Importantly, because of the difference in the number of patients with data for Asf1a and for Asf1b, we verified that there was no significant differences in the composition of the two populations of patients (data not shown).
We calculated correlations between various factors using the Pearson correlation coefficient method and analysed differences between groups with the Kruskal-Wallis test for continous variables. The disease-free interval is defined as the time from the diagnosis of breast cancer until the occurence of disease progression, meaning local recurrence in the treated breast, regional recurrence in lymph node-bearing areas, controlateral breast cancer or distant recurrences (metastasis). We determined a cut-off value that is prognostic for the disease free interval (DFI) by using a Cox proportional risks model and used the Wald test to evaluate the prognostic value of this variable on each event. We estimated the overall survival (OS), the metastasis-free interval and the DFI rates using the Kaplan-Meier method and compared the values between groups using a log-rank test. We carried out a multivariate analysis to assess the relative influence of certain prognostic factors (age, number of mitosis, grade, estrogen and progesteron-receptor status as well as p60, p150, HP1α, Asf1b, Ki67 expression levels)
on OS, DFI and metastasis free interval using the Cox stepwise forward procedure (Cox 1972) . The significance level was 0.05. We used the statistical software R (2.5.0 version) for our analyses. Red numbers together with an asterisk * indicates a significant p-value (p<0.05). A. Western blot analysis of total extracts from human U-2-OS cells showing the specific depletion of Asf1a, Asf1b or Asf1(a+b) for 48h by siRNA treatment with two independent sets of oligonucleotides. Increasing amounts (x) of total cell extracts are loaded. α-tubulin and Memcode serve as a loading control. We reveal Asf1a and Asf1b with a mix of the specific Asf1 antibodies and we reveal γH2A.X. M: molecular weight marker.
B.

B. Flow cytometry analysis of the cell cycle distribution of the cells shown in (A). Neither
Asf1a nor Asf1b depletions give any obvious phenotype during S phase. The upregulation of Asf1a in cells depleted of Asf1b ( Figure 3B ) could represent a compensatory mechanism to allow normal S phase progression.
C. (Left panel) Immunofluorescence analysis of PCNA staining in U-2-OS cells treated as in (A).
Representive mid S phase patterns are shown. DAPI stains nuclei. Scale bar is 10 µm. Asf1b expression levels significantly correlate with the grade of the tumor (left), with the occurence of metastasis at 5 years (middle) and with the disease free survival at 5 years (right). Results are analyzed and plotted using ONCOMINE database (Rhodes et al, 2004) .
Boxes represent the 25th-75th percentile, brackets: range; black line: median; black dots:
outliers; n: sample number. We considered p-values, based on Student's T-test, as significant when p ≤ 0.05.
B. Boxplot representation as in (A) of microarray expression levels of Asf1b in different types
of cancer (red) compared to normal tissue (blue). Results from transcriptome studies on different tumor types (Chen et al, 2002; Hendrix et al, 2006; Richardson et al, 2006; Su et al, 2007; Talantov et al, 2005) are analyzed and plotted using ONCOMINE database (Rhodes et al, 2004) . We considered p-values, based on Student's T-test, as significant when p ≤ 0.05.
Supplementary Table SI: List of all primary antibodies used in this study.
Company, as well as the order number, the lot number, the species and the dilutions for western blotting (WB) and immunofluorescence (IF) are provided for each antibody. Since Asf1a and Asf1b migrate at different positions in western blot (Sillje & Nigg, 2001 ), we used a mix of the specific Asf1 antibodies in western blot to recognize simultaneously the two isoforms. The specific purified antibodies against Asf1a or Asf1b were used separately in immunofluorescence.
Supplementary Table SII:
A. Table describing MAKVQVNNVVVLDNPSPFYNPFQFEITFECIEDLSEDLEWKIIYVGSAES 50 MAKVSVLNVAVLENPSPFHSPFRFEISFECSEALADDLEWKIIYVGSAES 50 ****.* **.**:*****:.**:***:*** * *::************** EEYDQVLDSVLVGPVPAGRHMFVFQADAPNPGLIPDADAVGVTVVLITCT 100 EEFDQILDSVLVGPVPAGRHMFVFQADAPNPSLIPETDAVGVTVVLITCT 100 **:**:*************************.***::************* YRGQEFIRVGYYVNNEYTETELRENPPVKPDFSKLQRNILASNPRVTRFH 150 YHGQEFIRVGYYVNNEYLNPELRENPPMKPDFSQLQRNILASNPRVTRFH 150 *:*************** :.*******:*****:**************** (p60) log (p60) log (Asf1a) log ( Normalized expression units Variables included in the model: mitotic index (qualitative), menopause status, ablation surgery quality, progesteron receptor status, Asf1b, Ki67
Variables included in the model: mitotic index (qualitative), tumor size (qualitative), menopause status, Asf1b, CAF-1 p60, Ki67
Variables included in the model: mitotic index (qualitative), ablation surgery quality, Asf1b, CAF-1 p60, Ki67
